The Regenstrief Institute Inc. and bioMérieux have signed an innovative landmark global collaboration agreement.
Use of LOINC codes enable laboratories, hospitals and other users of the diagnostics solutions and their results to assign the same unique identifier to a specific test no matter where it is used. Such standardization will improve patient care by ensuring the consistency and interoperability of test results in electronic medical record systems and health information exchange.
The Regenstrief Institute Inc. and bioMérieux have signed an innovative landmark global collaboration agreement under which experts from Regenstrief and bioMérieux will identify existing LOINC codes best describing bioMérieux in vitro diagnostic solutions and create new codes as needed.
Innovation and benefits for bioMérieux customers relies in the facts that this agreement will further develop the use of universal LOINC codes in transmissions from IVD devices to laboratory information systems. This will streamline the diagnostics solutions information and will reduce the efforts of laboratory and hospital professionals mapping laboratory tests to LOINC codes.
Discover more about bioMérieux, LOINC, the Regenstrief Institute through our web sites.
